-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Grace Therapeutics, Lowers Price Target to $8

Benzinga·04/24/2026 16:38:11
Listen to the news
TD Cowen analyst Stacy Ku maintains Grace Therapeutics (NASDAQ:GRCE) with a Buy and lowers the price target from $12 to $8.